To further confirm the regulation of AADAT by EGFR–AKT signaling in EGFR-mutant NSCLC cells, we treated an afatinib-resistant subline (PC9-AR-C3) with different generations of EGFR-TKIs, including gefitinib (first generation), afatinib (second generation), and osimertinib (third generation). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.